Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 278 results for coronavirus

  1. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. What is the effectiveness and safety of extended pharmacological venous thromboembolism (VTE) prophylaxis for people who have been discharged after treatment for COVID-19?

    (VTE) prophylaxis for people who have been discharged after treatment for COVID-19? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    10 August 2021

  3. Indoor air quality at home

    In development Reference number: GID-QS10113 Expected publication date: TBC

    Quality standard
    In development

  4. What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19?

    combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19? Any explanatory notes(if...

    Research recommendation
    Published
    12 November 2021

  5. Does early review and referral to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their life?

    to specialist palliative care services improve outcomes for adults with COVID-19 thought to be approaching the end of their...

    Research recommendation
    Published
    10 August 2021

  6. In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are the most accurate tests for diagnosing the infection and when should they be done?

    Recommendation ID NG191/12 Question In people with suspected COVID-19-associated pulmonary aspergillosis (CAPA), what are...

    Research recommendation
    Published
    17 December 2021

  7. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher...

    Research recommendation
    Published
    9 March 2022

  8. What pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised fatigue, breathlessness, and “brain fog”?

    pathophysiological mechanism(s) underlie the most common presentations of post-COVID-19 syndrome? For example, generalised...

    Research recommendation
    Published
    12 November 2021

  9. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors...

    Research recommendation
    Published
    10 August 2021

  10. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT) (NG200)

    This guideline has been withdrawn. VITT is associated with the COVID-19 Vaccine AstraZeneca, which is no longer available from the NHS. For people with COVID-19, see our guideline on managing COVID-19.

    Withdrawn guideline

  11. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots, including deep vein thrombosis and pulmonary embolism) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

    NICE guideline
    Last updated
    13 August 2019
    View recommendations

    Sections for NG89

  12. Does a multidisciplinary team agreed approach to weaning from continuous positive airway pressure improve weaning times and result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure?

    result in stopping continuous positive airway pressure for people with COVID-19 and acute respiratory failure? Any...

    Research recommendation
    Published
    12 November 2021

  13. Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma (TA680)

    Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    3 March 2021
    View recommendations

    Sections for TA680

  14. What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA), and their families or carers, on:• available tests for diagnosing CAPA• available treatments for CAPA?

    Question What are the views, preferences and experiences of people with COVID-19-associated pulmonary aspergillosis (CAPA),...

    Research recommendation
    Published
    9 March 2022

  15. What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a standard prophylactic dose for venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19?

    venous thromboembolism (VTE) prophylaxis in young people under 18 years with COVID-19? Any explanatory notes(if applicable)...

    Research recommendation
    Published
    10 August 2021